Delcath Systems - DCTH Stock Forecast, Price & News

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Analysts Set New Price Targets

Several equities analysts recently weighed in on DCTH shares. Canaccord Genuity Group cut their target price on shares of Delcath Systems from $24.00 to $20.00 and set a "buy" rating for the company in a research note on Monday, April 11th. BTIG Research decreased their price objective on shares of Delcath Systems from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, June 24th. Finally, StockNews.com assumed coverage on shares of Delcath Systems in a research note on Monday, August 1st. They issued a "sell" rating for the company.

Delcath Systems Price Performance

Delcath Systems stock traded up $0.20 during midday trading on Friday, reaching $4.36. The company's stock had a trading volume of 12,462 shares, compared to its average volume of 29,654. Delcath Systems has a fifty-two week low of $3.49 and a fifty-two week high of $11.95. The company has a debt-to-equity ratio of 2.55, a quick ratio of 2.70 and a current ratio of 2.93. The stock's 50 day simple moving average is $4.06 and its 200 day simple moving average is $5.44. The firm has a market capitalization of $34.49 million, a PE ratio of -1.21 and a beta of 0.93.

Delcath Systems (NASDAQ:DCTH - Get Rating) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.16). Delcath Systems had a negative return on equity of 246.07% and a negative net margin of 764.84%. The firm had revenue of $0.38 million for the quarter, compared to analyst estimates of $1.26 million. During the same period last year, the firm earned ($1.04) EPS. On average, equities research analysts forecast that Delcath Systems will post -3.15 earnings per share for the current year.

Insider Activity at Delcath Systems

In other news, CEO Gerard J. Michel bought 62,814 shares of the business's stock in a transaction that occurred on Wednesday, July 20th. The stock was purchased at an average price of $3.98 per share, with a total value of $249,999.72. Following the purchase, the chief executive officer now owns 125,864 shares of the company's stock, valued at approximately $500,938.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Steven A. J. Salamon bought 6,000 shares of the firm's stock in a transaction dated Thursday, May 12th. The stock was acquired at an average price of $4.90 per share, for a total transaction of $29,400.00. Following the acquisition, the director now owns 29,424 shares of the company's stock, valued at $144,177.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Gerard J. Michel purchased 62,814 shares of the firm's stock in a transaction on Wednesday, July 20th. The stock was bought at an average price of $3.98 per share, with a total value of $249,999.72. Following the acquisition, the chief executive officer now owns 125,864 shares in the company, valued at $500,938.72. The disclosure for this purchase can be found here. In the last quarter, insiders bought 72,114 shares of company stock valued at $294,613. 16.76% of the stock is owned by insiders.